- Home
- FENC vs SOR Comparison
FENC vs SOR Comparison
Compare FENC & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.75
Company Overview
Basic Information| Metric | FENC | SOR |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.8M | 383.4M |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | FENC | SOR |
|---|---|---|
| Price | $10.75 | $46.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $17.20 | N/A |
| AVG Volume (30 Days) | ★ 122.5K | 6.8K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $62.55 | N/A |
| Revenue Next Year | $42.10 | N/A |
| P/E Ratio | $164.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $44.20 |
| 52 Week High | $13.25 | $50.41 |
Technical Indicators
Market Signals| Indicator | FENC | SOR |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 66.59 |
| Support Level | $9.87 | $45.16 |
| Resistance Level | $11.07 | $47.35 |
| Average True Range (ATR) | 0.67 | 1.17 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 73.17 | 59.70 |
Price Performance
Historical Comparison FENC
SOR
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.